BRCA2 and adenocarcinoma: In the Villin-Cre+; Brca2fl/fl; Trp53fl/+ group (Group B), seven out of nine tested mice (78%) developed spontaneous and invasive adenocarcinomas at stomach and/or intestine sites, while no tumors detected in the Villin-Cre+; Brca2+/+; Trp53fl/+ group (Group A, 5/5 mice) (Fig. 1j).